Literature DB >> 10702388

Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

C Parravicini1, B Chandran, M Corbellino, E Berti, M Paulli, P S Moore, Y Chang.   

Abstract

Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is linked to KS, primary effusion lymphomas (PEL), and a subset of multicentric Castleman's disease (MCD). Transcript mapping studies using PEL cell lines have allowed preliminary classification of viral gene expression into constitutive (class I) and inducible (class II/III) categories. To determine whether viral gene expression differs in vivo, we examined tissue sections of KSHV-infected disorders, using specific antibodies against proteins that are representative of the different expression classes of KSHV genes. ORF73/LANA appears to be a surrogate marker for KSHV infection because it is constitutively expressed in vitro and in vivo in all KSHV-infected cells. Expression of vIRF1, vIL6, and PF-8 proteins in the infected B cells of MCD lymph nodes reproduces the expression pattern observed in TPA-stimulated KSHV-infected B-cell lines. In contrast, the protein expression of the inducible viral genes that we tested in KS and PEL biopsies is restricted to PF-8 and vIL6, respectively. The tightly restricted expression of KSHV proteins in vivo differs from the dysregulated expression of inducible KSHV genes in vitro and suggests that viral gene expression in KSHV-infected cell lines does not accurately reflect what occurs in diseased tissues. These differences may be related to either cell-specific or immune restriction of viral replication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702388      PMCID: PMC1876837          DOI: 10.1016/S0002-9440(10)64940-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

Authors:  P S Moore; C Boshoff; R A Weiss; Y Chang
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

2.  Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections.

Authors:  G Cattoretti; S Pileri; C Parravicini; M H Becker; S Poggi; C Bifulco; G Key; L D'Amato; E Sabattini; E Feudale
Journal:  J Pathol       Date:  1993-10       Impact factor: 7.996

3.  Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.

Authors:  G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

6.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

7.  Antioxidant-sensitive regulation of inflammatory-response genes in Kaposi's sarcoma cells.

Authors:  M K Offermann; J C Lin; E C Mar; R Shaw; J Yang; R M Medford
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-09

8.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.

Authors:  E Cesarman; P S Moore; P H Rao; G Inghirami; D M Knowles; Y Chang
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113

9.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  154 in total

1.  Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis.

Authors:  T Seo; J Park; D Lee; S G Hwang; J Choe
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator.

Authors:  J Chen; K Ueda; S Sakakibara; T Okuno; C Parravicini; M Corbellino; K Yamanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation.

Authors:  Marcel Pietrek; Melanie M Brinkmann; Ilona Glowacka; Anette Enlund; Anika Hävemeier; Oliver Dittrich-Breiholz; Michael Kracht; Marc Lewitzky; Kalle Saksela; Stephan M Feller; Thomas F Schulz
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells.

Authors:  Takahiro Watanabe; Makoto Sugaya; April M Atkins; Elisabeth A Aquilino; Aparche Yang; Debra L Borris; John Brady; Andrew Blauvelt
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 6.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

7.  Kaposi's sarcoma-associated herpesvirus viral protein kinase interacts with RNA helicase a and regulates host gene expression.

Authors:  Jae Eun Jong; Junsoo Park; Sunmi Kim; Taegun Seo
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

8.  Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Kathleen M Wyvill; Richard F Little; Michael J Iadarola; Joseph A Kovacs; Robert Yarchoan
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

9.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

10.  Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Authors:  Kristopher A Sarosiek; Lucas E Cavallin; Shruti Bhatt; Ngoc L Toomey; Yasodha Natkunam; Wilfredo Blasini; Andrew J Gentles; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.